Technology
Health
Pharmaceutical
Odonate Therapeutics
$22.329876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$22.32
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.02 (0.09%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ODT and other stocks, options, ETFs, and crypto commission-free!
About
Odonate Therapeutics, Inc. Common Stock, also called Odonate Therapeutics, is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. Read More It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The company was founded in March 2013 and is headquartered in San Diego, CA.
Employees
130
Headquarters
San Diego, California
Founded
2013
Market Cap
597.11M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
54.50K
High Today
$22.48
Low Today
$21.85
Open Price
$22.12
Volume
22.63K
52 Week High
$28.57
52 Week Low
$11.54
Collections
Technology
Health
Pharmaceutical
Therapy
Cancer Prevention
2017 IPO
US
North America
News
Yahoo FinanceApr 25
Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019
SAN DIEGO--(BUSINESS WIRE)-- Odonate Therapeutics, Inc. (ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31, 2019. As of March 31, 2019, Odonate had $112.1 million in cash, compared to $139.1 million as of December 31, 2018. This decrease in cash resulted primarily from net cash used in operating activities of $27.1 million. Odonate’s net l...
Price Paid on Robinhood
16% Higher
Right Now
52 Week Low
$11.54
Average Price Paid
$19.26
52 Week High
$28.57
Earnings
-$1.24
-$1.09
-$0.94
-$0.79
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Jul 30, Pre-Market